Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Dipankar De und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Pemphigus, Adrenal Cortex Hormones, Rituximab. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Pemphigus foliaceus (PF) is an uncommon autoimmune disease characterized by superficial blistering and erosions of the skin. The literature on PF globally is limited. Understanding clinicodemographic heterogeneity in PF is crucial for improving outcomes for affected individuals.
Objectives
To study the clinicodemographic characteristics and treatment outcomes of patients with PF in north India.
Methods
A retrospective study was conducted of patients with PF registered at the authors’ clinic at the Postgraduate Institute of Medical Education and Research in Chandigarh, north India, between November 2013 and June 2023.
Results
In total, 103 patients with PF were included in the study. The mean (SD) age at disease onset was 40.4 (15.7) years, with a male-to-female ratio of 1.7 : 1. The median duration of disease at presentation was 18 months (range 1–240). The most commonly prescribed treatment was topical corticosteroids (n = 98/103; 95.1%) or oral corticosteroids (n = 97/103; 94.2%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant and was used in 43.7% (n = 45/103) of patients. Overall, 75.7% (n = 78/103) of patients achieved clinical remission on minimal treatment (CRmin) in a mean of 6.5 (3.9) months. Clinical remission off treatment (CRoff) was achieved in 10.4 (6.0) months in 67.0% (n = 69/103) of patients. Among patients in the rituximab group, CRmin was achieved in 91.1% (n = 41/45) of patients in 6.3 (4.6) months and CRoff was achieved in 82.2% (n = 37/45) of patients in 9.0 (5.6) months.
Conclusions
In the present study PF was more common in men aged between 40 and 60 years. Corticosteroids (topical/systemic) formed the mainstay of treatment, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required for a better understanding of this disease in nonendemic locations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
ORCID-Profile: Dipankar De, Apoorva Sharma, Debajyoti Chatterjee, Rahul Mahajan, Sanjeev Handa
Zitieren
APA
De, D., Sharma, A., Hanumanthu, V., Chatterjee, D., Saikia, U. N., Saikia, B., Mahajan, R., & Handa, S. (2025). Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf408
Vancouver
De D, Sharma A, Hanumanthu V, Chatterjee D, Saikia UN, Saikia B, et al. Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf408
BibTeX
@article{De2025,
author = {De, Dipankar and Sharma, Apoorva and Hanumanthu, Vinod and Chatterjee, Debajyoti and Saikia, Uma Nahar and Saikia, Biman and Mahajan, Rahul and Handa, Sanjeev},
title = {Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf408}
}
EUVIMED